(VIANEWS) – Ecopetrol S.A. (EC), Inari Medical (NARI), Triumph Bancorp (TBK) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Ecopetrol S.A. (EC)

53% sales growth and 15.82% return on equity

Ecopetrol S.A. is an integrated oil-and gas company.

Ecopetrol S.A.’s sales growth this year is anticipated to be 56.9% and 3.5% for next year.

Year-on-year quarterly revenue growth grew by 130.3%, now sitting on N/A for the twelve trailing months.

Volume

Today’s last reported volume for Ecopetrol S.A. is 1220230 which is 5.55% below its average volume of 1291990.

Ecopetrol S.A.’s sales growth for the next quarter is 53%. The company’s growth estimates for the current quarter and the next is 454.5% and 600%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.82%.

Volatility

Ecopetrol S.A.’s last day, last week, and last month’s current intraday variation average was 1.60%, 1.73%, and 1.34%, respectively.

Ecopetrol S.A.’s highest amplitude of average volatility was 3.45% (day), 3.32% (last week), and 2.58% (last month), respectively.

Ecopetrol S.A.’s Stock Yearly Top and Bottom Value

Ecopetrol S.A.’s stock is valued at $19.32 at 01:22 EST, way higher than its 52-week high of $15.91.

Ecopetrol S.A.’s Moving Average

Ecopetrol S.A.’s worth is way above its 50-day moving average of $14.56 and way above its 200-day moving average of $13.53.

2. Inari Medical (NARI)

35.8% sales growth and 4.48% return on equity

Inari Medical, Inc. is a medical device company in commercial stage. It focuses its efforts on creating products that can transform the lives and treat venous disease patients in the United States.

Inari Medical’s sales growth this year is anticipated to be 28.8% and 21% for next year.

Year-on-year quarterly revenue growth grew by 71.2%, now sitting on 276.98M for the twelve trailing months.

Volume

Today’s last reported volume for Inari Medical is 699832 which is 32.26% above its average volume of 529103.

Inari Medical’s sales growth for the next quarter is 35.8%. The company’s growth estimates for the current quarter and the next is a negative 169.2% and negative -228.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.48%.

Volatility

Inari Medical’s last day, last week, and last month’s current intraday variation average was 2.62%, 1.96%, and 2.12%, respectively.

Inari Medical’s highest amplitude of average volatility was 4.93% (day), 4.69% (last week), and 4.77% (last month), respectively.

Inari Medical’s Stock Yearly Top and Bottom Value

Inari Medical’s stock is valued at $91.73 at 01:22 EST, way under its 52-week high of $116.41 and way above its 52-week low of $63.37.

Inari Medical’s Moving Average

Inari Medical’s worth is higher than its 50-day moving average of $83.70 and above its 200-day moving average of $84.28.

3. Triumph Bancorp (TBK)

21.5% sales growth and 14.25% return on equity

Triumph Bancorp, Inc. is a financial holding firm for TBK Bank, SSB. It provides diverse banking and commercial financing products and services to small and medium-sized companies in the United States.

Triumph Bancorp’s sales growth this year is anticipated to be 15% and 8.5% for next year.

Year-on-year quarterly revenue growth grew by 14.8%, now sitting on 432.46M for the twelve trailing months.

Volume

Today’s last reported volume for Triumph Bancorp is 407281 which is 119.48% above its average volume of 185565.

Triumph Bancorp’s sales growth for the next quarter is 21.5%. The company’s growth estimates for the current quarter and the next is a negative 25% and negative -5.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.25%.

Volatility

Triumph Bancorp’s last day, last week, and last month’s current intraday variation average was 2.90%, 3.40%, and 3.07%, respectively.

Triumph Bancorp’s highest amplitude of average volatility was 5.79% (day), 5.25% (last week), and 4.76% (last month), respectively.

Triumph Bancorp’s Stock Yearly Top and Bottom Value

Triumph Bancorp’s stock is valued at $84.87 at 01:22 EST, way under its 52-week high of $136.01 and way above its 52-week low of $69.01.

Triumph Bancorp’s Moving Average

Triumph Bancorp’s worth is under its 50-day moving average of $93.53 and way under its 200-day moving average of $98.40.

4. West Pharmaceutical (WST)

21.2% sales growth and 28.54% return on equity

West Pharmaceutical Services, Inc. produces and sells systems that contain and deliver injectable medicines and other healthcare products throughout the United States, Germany, Ireland, France, Ireland, France, Spain, Italy, Germany, France, Germany, Ireland, France, The United Kingdom, as well as internationally.

West Pharmaceutical’s sales growth this year is anticipated to be 30.4% and 8% for next year.

Year-on-year quarterly revenue growth grew by 37.3%, now sitting on 2.52B for the twelve trailing months.

Volume

Today’s last reported volume for West Pharmaceutical is 260849 which is 38.04% below its average volume of 421042.

West Pharmaceutical’s sales growth for the next quarter is 21.2%. The company’s growth estimates for the present quarter and the next is 56.5% and 41.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.54%.

Volatility

West Pharmaceutical’s last day, last week, and last month’s current intraday variation average was 2.36%, 2.19%, and 2.39%, respectively.

West Pharmaceutical’s highest amplitude of average volatility was 3.67% (day), 3.49% (last week), and 3.33% (last month), respectively.

West Pharmaceutical’s Stock Yearly Top and Bottom Value

West Pharmaceutical’s stock is valued at $372.40 at 01:22 EST, way below its 52-week high of $475.35 and way higher than its 52-week low of $253.85.

West Pharmaceutical’s Moving Average

West Pharmaceutical’s value is way below its 50-day moving average of $424.37 and below its 200-day moving average of $379.25.

5. EVO Payments (EVOP)

8.9% sales growth and 4.98% return on equity

EVO Payments, Inc. is an integrated merchant acquirer/payment processor in Europe and the Americas.

EVO Payments’s sales growth this year is expected to be 11.9% and 12.4% for next year.

Year-on-year quarterly revenue growth grew by 14.2%, now sitting on 496.64M for the twelve trailing months.

Volume

Today’s last reported volume for EVO Payments is 113764 which is 49.03% below its average volume of 223216.

EVO Payments’s sales growth for the next quarter is 8.9%. The company’s growth estimates for the present quarter and the next is 30.8% and 23.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.98%.

Volatility

EVO Payments’s last day, last week, and last month’s current intraday variation average was 1.16%, 2.24%, and 1.68%, respectively.

EVO Payments’s highest amplitude of average volatility was 2.91% (day), 3.25% (last week), and 3.07% (last month), respectively.

EVO Payments’s Stock Yearly Top and Bottom Value

EVO Payments’s stock is valued at $22.34 at 01:22 EST, way below its 52-week high of $30.46 and way above its 52-week low of $20.07.

EVO Payments’s Moving Average

EVO Payments’s value is below its 50-day moving average of $23.51 and below its 200-day moving average of $24.49.

6. ProLogis (PLD)

6.6% sales growth and 4.62% return on equity

Prologis, Inc., is a global leader in logistics real property with a special focus on high growth, high-barrier markets.

ProLogis’s sales growth this year is expected to be 8.7% and 7.1% for next year.

Year-on-year quarterly revenue growth declined by 7.3%, now sitting on 4.79B for the twelve trailing months.

Volume

Today’s last reported volume for ProLogis is 1683140 which is 44.45% below its average volume of 3030220.

ProLogis’s sales growth for the next quarter is 6.6%. The company’s growth estimates for the present quarter and the next is 30% and 42.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.62%.

Volatility

ProLogis’s last day, last week, and last month’s current intraday variation average was 0.18%, 0.43%, and 0.85%, respectively.

ProLogis’s highest amplitude of average volatility was 1.17% (day), 1.40% (last week), and 1.96% (last month), respectively.

ProLogis’s Stock Yearly Top and Bottom Value

ProLogis’s stock is valued at $162.99 at 01:22 EST, above its 52-week high of $161.11.

ProLogis’s Moving Average

ProLogis’s worth is way above its 50-day moving average of $145.84 and way above its 200-day moving average of $127.11.

7. Ameren (AEE)

5.9% sales growth and 10.4% return on equity

Ameren’s sales growth this year is expected to be 6.1% and 4.4% for next year.

Year-on-year quarterly revenue growth grew by 5.5%, now sitting on 5.74B for the twelve trailing months.

Volume

Today’s last reported volume for Ameren is 522337 which is 60.5% below its average volume of 1322460.

Ameren’s sales growth for the next quarter is 5.9%. The company’s growth estimates for the current quarter and the next is 8.8% and negative 0%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.4%.

Volatility

Ameren’s last day, last week, and last month’s current intraday variation average was 0.18%, 0.11%, and 0.29%, respectively.

Ameren’s highest amplitude of average volatility was 1.40% (day), 1.17% (last week), and 1.23% (last month), respectively.

Ameren’s Stock Yearly Top and Bottom Value

Ameren’s stock is valued at $95.75 at 01:22 EST, higher than its 52-week high of $90.77.

Ameren’s Moving Average

Ameren’s worth is way higher than its 50-day moving average of $84.29 and way higher than its 200-day moving average of $83.91.

LEAVE A REPLY

Please enter your comment!
Please enter your name here